Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study

Background: People who use drugs (PWUD) are a key target population to reduce the burden of hepatitis C virus (HCV) infection. Aim: To assess risk factors and temporal trends of active HCV infection in PWUD in Madrid, Spain. Methods: We conducted a retrospective study between 2017 and 2023, includin...

Descripción completa

Detalles Bibliográficos
Autores: Ryan, Pablo, Valencia, Jorge, Cuevas, Guillermo, Amigot-Sánchez, Rafael, Martinez, Isidoro, Lazarus, Jeffrey V, Perez-Garcia, Felipe, Resino, Salvador
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/26428
Acceso en línea:https://hdl.handle.net/20.500.12105/26428
Access Level:acceso abierto
Palabra clave:Hepatitis C
Spain
Epidemiology
Mobile screening unit
People who inject drugs
People who use drugs
Adult
Drug Users
Female
Hepacivirus
Hepatitis C Antibodies
Humans
Male
Middle Aged
Prevalence
Retrospective Studies
Risk Factors
Risk-Taking
Sexual Behavior
Substance Abuse, Intravenous
Substance-Related Disorders
Surveys and Questionnaires
Young Adult
id ES_65bbf9ca3e44870e73535754cb4e3346
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/26428
network_acronym_str ES
network_name_str España
repository_id_str
spelling Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective studyRyan, PabloValencia, JorgeCuevas, GuillermoAmigot-Sánchez, RafaelMartinez, IsidoroLazarus, Jeffrey VPerez-Garcia, FelipeResino, SalvadorHepatitis CSpainEpidemiologyMobile screening unitPeople who inject drugsPeople who use drugsAdultDrug UsersFemaleHepacivirusHepatitis C AntibodiesHepatitis CHumansMaleMiddle AgedPrevalenceRetrospective StudiesRisk FactorsRisk-TakingSexual BehaviorSpainSubstance Abuse, IntravenousSubstance-Related DisordersSurveys and QuestionnairesYoung AdultBackground: People who use drugs (PWUD) are a key target population to reduce the burden of hepatitis C virus (HCV) infection. Aim: To assess risk factors and temporal trends of active HCV infection in PWUD in Madrid, Spain. Methods: We conducted a retrospective study between 2017 and 2023, including 2,264 PWUD visiting a mobile screening unit. Data about epidemiology, substance use and sexual risk behaviour were obtained through a 92-item questionnaire. HCV was detected by antibody test, followed by RNA test. The primary outcome variable was active HCV infection prevalence, calculated considering all individuals who underwent RNA testing and analysed by logistic regression adjusted by the main risk factors. Results: Of all participants, 685 tested positive for anti-HCV antibodies, and 605 underwent RNA testing; 314 had active HCV infection, and 218 initiated treatment. People who inject drugs (PWID) were identified as the main risk group. The active HCV infection rate showed a significant downward trend between 2017 and 2023 in the entire study population (23.4% to 6.0%), among PWID (41.0% to 15.0%) and PWUD without injecting drug use (7.0% to 1.3%) (p < 0.001 for all). These downward trends were confirmed by adjusted logistic regression for the entire study population (adjusted odds ratio (aOR): 0.78), PWID (aOR: 0.78), and PWUD non-IDU (aOR: 0.78). Conclusions: Our study demonstrates a significant reduction in active HCV infection prevalence among PWUD, particularly in PWID, which suggests that efforts in the prevention and treatment of HCV in Madrid, Spain, have had an impact on the control of HCV infection.European Centre for Disease Prevention and Control (ECDC)Gilead Sciences (Spain)Instituto de Salud Carlos IIIAbbVieMinisterio de Ciencia e Innovación (España)Unión Europea. Comisión Europea. NextGenerationEUCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)Asociación Española para el Estudio del HígadoMadrid Positivo Association20252025-03-1220242024-07-0120242024-07-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfapplication/pdfhttps://hdl.handle.net/20.500.12105/26428reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)InglésengES PI20CIII 00004ES PI19CIII 00009ES CB21 13open accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/264282026-06-12T12:43:37Z
dc.title.none.fl_str_mv Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
title Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
spellingShingle Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
Ryan, Pablo
Hepatitis C
Spain
Epidemiology
Mobile screening unit
People who inject drugs
People who use drugs
Adult
Drug Users
Female
Hepacivirus
Hepatitis C Antibodies
Hepatitis C
Humans
Male
Middle Aged
Prevalence
Retrospective Studies
Risk Factors
Risk-Taking
Sexual Behavior
Spain
Substance Abuse, Intravenous
Substance-Related Disorders
Surveys and Questionnaires
Young Adult
title_short Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
title_full Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
title_fullStr Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
title_full_unstemmed Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
title_sort Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
dc.creator.none.fl_str_mv Ryan, Pablo
Valencia, Jorge
Cuevas, Guillermo
Amigot-Sánchez, Rafael
Martinez, Isidoro
Lazarus, Jeffrey V
Perez-Garcia, Felipe
Resino, Salvador
author Ryan, Pablo
author_facet Ryan, Pablo
Valencia, Jorge
Cuevas, Guillermo
Amigot-Sánchez, Rafael
Martinez, Isidoro
Lazarus, Jeffrey V
Perez-Garcia, Felipe
Resino, Salvador
author_role author
author2 Valencia, Jorge
Cuevas, Guillermo
Amigot-Sánchez, Rafael
Martinez, Isidoro
Lazarus, Jeffrey V
Perez-Garcia, Felipe
Resino, Salvador
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Gilead Sciences (Spain)
Instituto de Salud Carlos III
AbbVie
Ministerio de Ciencia e Innovación (España)
Unión Europea. Comisión Europea. NextGenerationEU
Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
Asociación Española para el Estudio del Hígado
Madrid Positivo Association
dc.subject.none.fl_str_mv Hepatitis C
Spain
Epidemiology
Mobile screening unit
People who inject drugs
People who use drugs
Adult
Drug Users
Female
Hepacivirus
Hepatitis C Antibodies
Hepatitis C
Humans
Male
Middle Aged
Prevalence
Retrospective Studies
Risk Factors
Risk-Taking
Sexual Behavior
Spain
Substance Abuse, Intravenous
Substance-Related Disorders
Surveys and Questionnaires
Young Adult
topic Hepatitis C
Spain
Epidemiology
Mobile screening unit
People who inject drugs
People who use drugs
Adult
Drug Users
Female
Hepacivirus
Hepatitis C Antibodies
Hepatitis C
Humans
Male
Middle Aged
Prevalence
Retrospective Studies
Risk Factors
Risk-Taking
Sexual Behavior
Spain
Substance Abuse, Intravenous
Substance-Related Disorders
Surveys and Questionnaires
Young Adult
description Background: People who use drugs (PWUD) are a key target population to reduce the burden of hepatitis C virus (HCV) infection. Aim: To assess risk factors and temporal trends of active HCV infection in PWUD in Madrid, Spain. Methods: We conducted a retrospective study between 2017 and 2023, including 2,264 PWUD visiting a mobile screening unit. Data about epidemiology, substance use and sexual risk behaviour were obtained through a 92-item questionnaire. HCV was detected by antibody test, followed by RNA test. The primary outcome variable was active HCV infection prevalence, calculated considering all individuals who underwent RNA testing and analysed by logistic regression adjusted by the main risk factors. Results: Of all participants, 685 tested positive for anti-HCV antibodies, and 605 underwent RNA testing; 314 had active HCV infection, and 218 initiated treatment. People who inject drugs (PWID) were identified as the main risk group. The active HCV infection rate showed a significant downward trend between 2017 and 2023 in the entire study population (23.4% to 6.0%), among PWID (41.0% to 15.0%) and PWUD without injecting drug use (7.0% to 1.3%) (p < 0.001 for all). These downward trends were confirmed by adjusted logistic regression for the entire study population (adjusted odds ratio (aOR): 0.78), PWID (aOR: 0.78), and PWUD non-IDU (aOR: 0.78). Conclusions: Our study demonstrates a significant reduction in active HCV infection prevalence among PWUD, particularly in PWID, which suggests that efforts in the prevention and treatment of HCV in Madrid, Spain, have had an impact on the control of HCV infection.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-07-01
2024
2024-07-01
2025
2025-03-12
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/26428
url https://hdl.handle.net/20.500.12105/26428
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv ES PI20CIII 00004
ES PI19CIII 00009
ES CB21 13
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv European Centre for Disease Prevention and Control (ECDC)
publisher.none.fl_str_mv European Centre for Disease Prevention and Control (ECDC)
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409764529668096
score 15.811543

Similares en LA Referencia